AIM ImmunoTech Inc (AIM)
0.223
-0.03
(-11.75%)
USD |
NYAM |
Nov 15, 16:00
0.2249
0.00 (0.00%)
After-Hours: 20:00
AIM ImmunoTech Research and Development Expense (TTM): 9.03M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 9.03M |
| March 31, 2024 | 10.84M |
| December 31, 2023 | 10.94M |
| September 30, 2023 | 9.846M |
| June 30, 2023 | 8.484M |
| March 31, 2023 | 8.006M |
| December 31, 2022 | 6.99M |
| September 30, 2022 | 7.806M |
| June 30, 2022 | 8.44M |
| March 31, 2022 | 7.282M |
| December 31, 2021 | 7.67M |
| September 30, 2021 | 7.022M |
| June 30, 2021 | 6.118M |
| March 31, 2021 | 6.264M |
| December 31, 2020 | 5.738M |
| September 30, 2020 | 4.90M |
| June 30, 2020 | 4.988M |
| March 31, 2020 | 4.621M |
| December 31, 2019 | 4.651M |
| September 30, 2019 | 4.201M |
| June 30, 2019 | 4.606M |
| March 31, 2019 | 4.851M |
| December 31, 2018 | 4.778M |
| September 30, 2018 | 4.605M |
| June 30, 2018 | 3.797M |
| Date | Value |
|---|---|
| March 31, 2018 | 3.562M |
| December 31, 2017 | 4.098M |
| September 30, 2017 | 5.147M |
| June 30, 2017 | 5.702M |
| March 31, 2017 | 5.496M |
| December 31, 2016 | 5.107M |
| September 30, 2016 | 4.201M |
| June 30, 2016 | 4.827M |
| March 31, 2016 | 6.366M |
| December 31, 2015 | 8.038M |
| September 30, 2015 | 9.519M |
| June 30, 2015 | 9.445M |
| March 31, 2015 | 9.336M |
| December 31, 2014 | 8.988M |
| September 30, 2014 | 8.083M |
| June 30, 2014 | 8.362M |
| March 31, 2014 | 8.35M |
| December 31, 2013 | 8.36M |
| September 30, 2013 | 10.58M |
| June 30, 2013 | 10.76M |
| March 31, 2013 | 10.18M |
| December 31, 2012 | 9.508M |
| September 30, 2012 | 7.466M |
| June 30, 2012 | 6.859M |
| March 31, 2012 | 6.747M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
4.621M
Minimum
Mar 2020
10.94M
Maximum
Dec 2023
7.349M
Average
7.282M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Perspective Therapeutics Inc | 28.53M |
| Protalix BioTherapeutics Inc | 12.62M |
| Electromed Inc | 0.656M |
| Xtant Medical Holdings Inc | 2.145M |
| Armata Pharmaceuticals Inc | 32.40M |